INNOVATE Corp. (NYSE:VATE) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Anthony Rozmus - Investor Relations Paul Voigt - Interim Chief Executive Officer Mike Sena - Chief Financial Officer Conference Call Participants Brian Charles - R.W. Pressprich Operator Good afternoon, and welcome to INNOVATE Corp. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] Please note, this event is being recorded. I would no ...

CS Disco, Inc. (NYSE:LAW) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Aleksey Lakchakov - Head of Investor Relations Eric Friedrichsen - Chief Executive Officer Michael Lafair - Chief Financial Officer Ian Black - Needham & Company Conference Call Participants Koji Ikeda - Bank of America Brian Essex - JPMorgan Mark Schappel - Loop Capital Ian Black - Needham & Company Operator Ladies and gentlemen, thank you for standing by, and welcome to CS Disco's Third Quarter of F ...

PTC Inc. (NASDAQ:PTC) Q4 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Matt Shimao - Head of Investor Relations Neil Barua - President and Chief Executive Officer Kristian Talvitie - Executive Vice President and Chief Financial Officer Conference Call Participants Ken Wong - Oppenheimer & Co. Inc. Daniel Jester - BMO Capital Markets Saket Kalia - Barclays Capital Joseph Vruwink - Robert W. Baird & Co. Adam Borg - Stifel, Nicolaus & Company Jay Vleeschhouwer - Griffin Securit ...

Dutch Bros, Inc. (NYSE:BROS) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Paddy Warren - Senior Director, IR and Capital Markets Christine Barone - President & CEO Josh Guenser - CFO Conference Call Participants Dennis Geiger - UBS Patrick Johnson - Stifel Andrew Charles - TD Cowen Sara Senatore - Bank of America Merrill Lynch Gregory Francfort - Guggenheim Partners Andy Barish - Jefferies David Tarantino - Baird Nick Setyan - Wedbush Securities Rahul Kro - JPMorgan Jeff ...

Superior Group of Companies, Inc. (NASDAQ:SGC) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Michael Benstock - Chief Executive Officer Mike Koempel - Chief Financial Officer Conference Call Participants Kevin Steinke - Barrington Research Jim Sidoti - Sidoti & Company Keegan Cox - D.A. Davidson David Marsh - Singular Research Operator Good afternoon everyone. Welcome to the Superior Group of Companies' Third Quarter 2024 Conference Call. With us today, are Michael Bensto ...

Myomo, Inc. (NYSE:MYO) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Kim Golodetz - LHA Investor Relations Paul Gudonis - CEO Dave Henry - CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Scott Henry - AGP Anthony Vendetti - Maxim Group Ben Haynor - Lake Street Capital Markets Edward Woo - Ascendiant Capital Operator Good day, and welcome to the Myomo Third Quarter 2024 Financial Results Conference Call. [Operator Instructions]. I would now like to turn ...

Financial Data and Key Metrics - Total revenue grew 34% to a record $191.5 million in Q3 2024, driven by precision oncology revenue, which increased 35% to $180.6 million [11][39] - Clinical test volume grew 21% year-over-year and 7% quarter-over-quarter, reaching 53,100 tests in Q3 2024 [12][40] - Biopharma test volume increased 40% year-over-year to a record 10,500 tests in Q3 2024 [13][41] - Guardant360 ASP reached $3,000 in Q3 2024, achieving the long-term goal four years ahead of schedule [17][43] - Non-GAAP gross margin excluding screening was 65% in Q3 2024, with adjusted EBITDA loss improving to $56.2 million [46][48] - Free cash flow improved to negative $55.3 million in Q3 2024, with $1 billion in cash on hand [49][50] Business Line Performance - Guardant360 LVT upgrade expanded the number of genes by nearly tenfold, improved sensitivity for tumor burden detection by a factor of 10, and introduced methylation tech stack features [14][15] - Guardant360 LVT on smart liquid biopsy was the strongest contributor to year-over-year and sequential volume growth in Q3 2024 [17] - Reveal continues to see strong growth, with clinical validity studies for additional cancers such as lung, pancreatic, and gastric planned for 2025 [24][25] - Shield, the first FDA-approved blood test for colorectal cancer screening, launched in August 2024 with a Medicare price of $920 [29][34] Market Performance - The company partnered with Policlinico Gemelli in Rome to implement on-site processing of Guardant360 CDx tests, marking one of the first dedicated liquid biopsy testing facilities in Italy [19] - Strong momentum in China with a growing pipeline of biopharma samples [22] - Shield received a Medicare price of $920, with expectations to secure an ADLT designation and a more favorable Medicare price of $14.95 in 2025 [34] Strategic Direction and Industry Competition - The company aims to achieve greater than 60% gross margins for its MRD business, with Reveal expected to be gross margin positive in 2025 [26][27] - Shield is positioned to become a leading multi-cancer detection blood test, with plans to upgrade to Shield V2 in 2025 [37] - The company expects oncology clinical volume growth to accelerate above 20% in 2025, driven by Guardant360, Reveal, and TissueNext [54] Management Commentary on Operating Environment and Future Outlook - Management highlighted the significant survival benefits of using Guardant360 CDx in the SCRUM-Japan GOZILA study, with 24% of patients receiving personalized targeted treatment based on Guardant360 CDx [20] - The company is optimistic about the potential inclusion of Shield in American Cancer Society guidelines and expects to secure ADLT status in 2025 [37] - Management reiterated confidence in achieving cash flow breakeven by 2028, with the potential to bring forward the target date due to the early achievement of Guardant360 ASP goals [50] Other Important Information - The company increased its full-year 2024 revenue guidance to $720 million to $725 million, representing growth of approximately 28% to 29% compared to 2023 [51] - Shield's initial post-launch volume was ahead of expectations, with strong momentum continuing into Q4 2024 [33] - The company expects to report Shield revenue and volume separately in Q4 2024 as they become material to the numbers [42] Q&A Session Summary Question: Shield's Medicare pricing and sales strategy [56] - The company remains committed to a disciplined investment approach for Shield, with a maximum spend of $200 million in the following years [57] - While USPSTF recommendations are seen as a major milestone, the company believes there is significant market depth to mine in the covered patient population [60] Question: Shield's performance and market feedback [63] - Shield's initial volume post-launch was ahead of expectations, with strong momentum continuing into Q4 2024 [65] - The company plans to report Shield volume and revenue contribution in Q4 2024 [65] Question: Therapy selection TAM and repeat testing [71] - The market for therapy selection is expected to grow significantly, with potential for patients to receive multiple tests over their lifetime [72] - The company sees liquid biopsy as uniquely positioned to capture this market due to its ability to perform repeat testing easily [73] Question: Reveal's potential upside and ASP [74] - The company expects an acceleration in Reveal volume growth in 2025, driven by CRC surveillance reimbursement and cost reduction initiatives [76] - ASP for Reveal is expected to increase with CRC surveillance reimbursement, though the exact uptick is difficult to quantify at this stage [76] Question: Shield's market penetration and V2 data [78] - Shield V2 data is expected in 2025, with potential for an upgrade to the test [79] - The company assumes a 60% market share in blood-based CRC screening in its long-term projections [80] Question: Core revenue growth and Shield reordering rates [83] - Prior period cash upsides contributed approximately $20 million to revenue growth, with the remainder driven by clinical volume growth, Guardant360 ASP increases, and biopharma performance [84] - Reordering rates for Shield are not yet measurable, as the recommended interval for retesting is every three years [85] Question: Clinical volume growth acceleration and Shield lab setup [87] - Clinical volume growth is expected to accelerate above 20% in 2025, driven by Guardant360, TissueNext, and Reveal [89] - The company has incorporated learnings from the LDT launch into the Shield commercial launch, with 15% of orders coming from accounts with full EMR integration [91] Question: Reveal's contribution and COSMOS progress [94] - Reveal contributed to sequential growth in Q3 2024, with the company expecting 2025 to be a pivotal year for the product [98] - The company is making progress on CRC surveillance reimbursement and expects to submit breast data for publication soon [96] Question: International growth and Reveal acceleration [100] - The main growth driver for clinical volume acceleration in 2025 is expected to be Guardant360 in the U.S., with international growth playing a smaller role [101] - Reveal volume acceleration is expected regardless of CRC surveillance reimbursement, though reimbursement will allow for more aggressive growth [103] Question: Japan market and lab closure [105] - The closure of the Shonan Research Center in Japan was unrelated to market progress and was a cost-cutting measure [106] - The ramp in Japan has been slower than expected due to reimbursement structures, but the company remains optimistic about future growth [107] Question: Guidance increase and Shield volume estimation [109] - The increase in full-year revenue guidance was driven by prior period cash upsides, Guardant360 ASP increases, biopharma revenue growth, and Shield revenue contribution [113] - Shield's cost per test has decreased below $1,000, with further reductions expected as volume scales [115]

Red Violet, Inc. (NASDAQ:RDVT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Camilo Ramirez - Senior Vice President of Finance and Investor Relations Derek Dubner - Chairman and Chief Executive Officer Dan MacLachlan - Chief Financial Officer Conference Call Participants Josh Nichols - B. Riley Operator Good day, ladies and gentlemen, and welcome to Red Violet's Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After th ...

HubSpot, Inc. (NYSE:HUBS) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Ryan Burkart - Senior Director, Investor Relations Yamini Rangan - Chief Executive Officer Kate Bueker - Chief Financial Officer Dharmesh Shah - Co-Founder & Chief Technology Officer Conference Call Participants Mark Murphy - JPMorgan Rishi Jaluria - RBC Capital Markets Samad Samana - Jefferies Kirk Materne - Evercore ISI Alex Zukin - Wolfe Research Bradley Sills - Bank of America Merrill Lynch Michae ...

Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants G.J. Hart - President & Chief Executive Officer Todd Wilson - Chief Financial Officer Conference Call Participants Todd Brooks - The Benchmark Company Alex Slagle - Jefferies Alex Sturnieks - Lake Street Capital Andrew Wolf - C.L. King Operator Good afternoon, everyone, and welcome to the Red Robin Gourmet Burgers Incorporated Third Quarter 2024 Earnings Call. This conference is be ...